Merck To Spend Up To $2.3B In Ablynx Licensing Deal

Law360, New York (February 3, 2014, 6:26 PM EST) -- Belgian biopharmaceutical company Ablynx NV has inked a licensing agreement with Merck & Co. Inc. worth up to €1.7 billion ($2.3 billion) to develop methods for the body to fight cancer by activating the immune system, the companies said Monday.

Under the deal, a Merck subsidiary will pay Ablynx €20 million upfront and up to €10.7 million in research funding during the initial three-year research term of the collaboration. Ablynx can also receive development, regulatory and commercial milestone payments on achieved sales thresholds for a number...
To view the full article, register now.

UK Financial Services

UK Financial Services

Read Our Latest UK Financial Services Coverage

Financial Services Law360 UK provides breaking news and analysis on the financial sector. Coverage includes UK and European Union policy, enforcement, and litigation involving banks, asset management firms, and other financial services organizations.